Simon Read's most recent trade in Dianthus Therapeutics Inc was a trade of 6,090 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 21, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics Inc | Simon Read | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 6,090 | 6,090 | - | - | Stock Option (Right to Buy) | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 189,043 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 150,517 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 14.50 per share. | 27 Apr 2026 | 143,595 | 0 (0%) | 0% | 14.5 | 2,082,128 | Common Stock |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 99,073 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.25 per share. | 26 Dec 2025 | 71,303 | 143,595 (0%) | 0% | 14.3 | 1,016,068 | Common Stock |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.60 per share. | 21 Aug 2025 | 12,529 | 214,898 (0%) | 0% | 7.6 | 95,220 | Common Stock |
| Dianthus Therapeutics Inc | Simon Read | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 150,517 | 150,517 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 83,073 | 227,427 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.31 per share. | 02 Jan 2025 | 7,482 | 144,354 (0%) | 0% | 9.3 | 69,657 | Common Stock |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.09 per share. | 21 Aug 2024 | 12,529 | 151,836 (0%) | 0% | 12.1 | 151,476 | Common Stock |
| Amicus Therapeutics Inc | Nicolas Reade Simon Harford | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 99,073 | 99,073 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Nicolas Reade Harford Simon | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 57,392 | 164,365 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2023 | 189,043 | 189,043 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Simon Nicolas Reade Harford | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2023 | 106,973 | 106,973 (0%) | 0% | 0 | Common Stock |